Astrocytoma and Oligodendroglioma
Astrocytomas and oligodendrogliomas are primary brain tumors defined by distinct glial cell origins. Molecular markers help refine diagnosis and therapeutic selection.
Biomarkers used in this indication
Each approval combines this indication with specific biomarker criteria and a therapy. Select a therapy from the tables below to open its FDA-defined testing pathway.
Defined explicitly for Astrocytoma and Oligodendroglioma in FDA labeling.
| Biomarker | Biomarker criteria | Therapies |
|---|---|---|
| IDH1, IDH2 |
|
Defined at the solid tumor level and applicable to Astrocytoma and Oligodendroglioma and other solid tumor cancers.
Therapies with biomarker-defined approvals
Each therapy below has at least one FDA companion diagnostic approval tied to Astrocytoma and Oligodendroglioma. Select a therapy to view the specific approval and eligible tests.
deficient mismatch repair (dMMR) proteins (MLH1, PMS2, MSH2 and MSH6); MSI-High (Microsatellite instability-High)
deficient mismatch repair (dMMR) proteins (MLH1, PMS2, MSH2 and MSH6); MSI-High (Microsatellite instability-High); TMB (TMB ≥ 10 mutations per megabase)
RET (fusions)
NTRK1, NTRK2 and NTRK3 (fusions)
NTRK1, NTRK2 and NTRK3 (fusions)
IDH1, IDH2 (IDH1 R132C, IDH1 R132G, IDH1 R132H, IDH1 R132L, IDH1 R132S, IDH2 R172M, IDH2 R172K, IDH2 R172W, IDH2 R172S, and IDH2 R172G mutations)